Status:
COMPLETED
Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.
Lead Sponsor:
Lund University Hospital
Collaborating Sponsors:
Hoffmann-La Roche
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Patients with metastatic colorectal cancer will be treated with chemotherapy according to investigators choice. In addition to chemotherapy treatment, treatment with bevacizumab will be given concomit...
Eligibility Criteria
Inclusion
- Untreated metastatic colorectal carcinoma
- Age 18 yrs or over
- Measurable disease according to Response Evaluation Criteria in solid Tumors (RECIST criteria)
- ECOG performance status 0 or 1
- Life expectancy more than 3 months
- Adequate haematological, renal and liver function
- Tumor tissue available for determination of KRAS mutational status
- Blood sample and paraffin embedded tumor tissue for translational research
Exclusion
- Adjuvant therapy within 6 months
- CNS metastases
- Clinically significant atherosclerotic vascular disease
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
233 Patients enrolled
Trial Details
Trial ID
NCT01229813
Start Date
October 1 2010
End Date
December 1 2013
Last Update
April 13 2015
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital
Odense, Denmark
2
County Hospital Ryhov
Jönköping, Sweden
3
County Hospital
Kalmar, Sweden
4
Central Hospital
Karlstad, Sweden